[Verapamil in the treatment of patients with coronary insufficiency].
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001049:Apnea / Q000139:chemically induced; D001161:Arteriosclerosis / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002302:Cardiac Output / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D003331:Coronary Vessels / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D012039:Regional Blood Flow; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D002301:Cardiac Glycosides; D009570:Nitriles; D014665:Vasodilator Agents; D014700:Verapamil
Die Behandlung coronarinsuffizienter Patienten mit Verapamil.